Gilead – Talk Bio

Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial

2 weeks ago talkbio0Tagged Arcus, domvanalimab, Gilead, Malignant neoplasm of stomach, TIGIT gene, zimberelimab

Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab

Gilead’s Kite to Acquire Interius for $350M, Advancing In Vivo CAR-T Therapy

2 months ago talkbio0Tagged Acquisition, CAR-T, CAR-T therapy, Cell Therapy, Gilead, in vivo, Interius BioTherapeutics, Kite, device (physical object), Tecartus, Yescarta

Gilead; Kite; Interius BioTherapeutics; CAR-T therapy; in vivo CAR-T; acquisition; off-the-shelf cell therapy; $350 million; biotech; Yescarta; Tecartus; cell therapy platform

WHO to Develop Guidelines for Gilead’s Twice-Yearly HIV PrEP Injection (Lenacapavir)

4 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization

WHO; Gilead; Lenacapavir; twice-yearly injection; PrEP; HIV prevention; guidelines; FDA approval

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

4 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

4 months ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

4 months ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, Long-acting injectable, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization, Yeztugo

Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines

Gilead, ‘closely attuned to’ potential US policy shifts, stands by long-acting PrEP launch

6 months ago talkbio0Tagged Gilead, HIV Prevention, launch, Lenacapavir, long-acting, Pre-Exposure Prophylaxis, U.S., United States Food and Drug Administration

Lenacapavir, Pre-Exposure Prophylaxis, United States Food and Drug Administration, launch, HIV prevention, long-acting, U.S., Gilead

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

7 months ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.